AbbVie (ABBV) Wins EU Approval For RINVOQ In Vitiligo And Alopecia

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

AbbVie (NYSE:ABBV) received European Commission approval for RINVOQ (upadacitinib) as the first systemic treatment in the EU for non segmental vitiligo. The decision also covers RINVOQ as a systemic option for severe alopecia areata in adults and adolescents. These approvals expand RINVOQ's labeled uses in Europe and add new indications in dermatology and immunology.

For investors following AbbVie, this move adds fresh detail to the story around its immunology franchise. The company develops and commercializes therapies in areas such as immunology, oncology and neuroscience, and RINVOQ already sits at the center of that portfolio. The new EU indications come as regulators and companies continue to focus on treatments for chronic immune mediated conditions with limited prior options.

These approvals give AbbVie additional ways to position RINVOQ in Europe across dermatology and immunology. Investors may monitor treatment uptake, reimbursement decisions and real world safety data to assess the commercial impact of these indications over time.

Stay updated on the most important news stories for AbbVie by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbbVie.NYSE:ABBV Earnings & Revenue Growth as at Jul 2026

2 things going right for AbbVie that this headline doesn't cover.

Investor Checklist

Quick Assessment

⚖️ Price vs Analyst Target: AbbVie trades at US$257.41, which is about 4.2% below the average analyst price target of US$268.68. ✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading about 45.2% below the Simply Wall St estimate of fair value. ✅ Recent Momentum: The stock is up 2.3% over the last 30 days.

There's only one way to know the right time to buy, sell or hold AbbVie. Head to Simply Wall St's company report for the latest analysis of AbbVie's Fair Value.

Key Considerations

📊 The new EU approvals for RINVOQ in non segmental vitiligo and severe alopecia areata broaden AbbVie's immunology reach into areas with limited systemic treatment options. 📊 Watch for prescription trends, reimbursement decisions across key EU markets, and any commentary on RINVOQ's contribution to AbbVie's US$62.8b revenue base. ⚠️ Risk checks highlight issues such as high debt, negative shareholders' equity, and a 2.69% dividend that is not well covered by earnings.

Dig Deeper

For the full picture including more risks and rewards, check out the complete AbbVie analysis. Alternatively, you can check out the community page for AbbVie to see how other investors believe this latest news will impact the company's narrative.

Story Continues

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ABBV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments